請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22192完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉(Ming-Whei Yu) | |
| dc.contributor.author | Bo-Yu Hsiao | en |
| dc.contributor.author | 蕭博育 | zh_TW |
| dc.date.accessioned | 2021-06-08T04:13:37Z | - |
| dc.date.copyright | 2010-09-09 | |
| dc.date.issued | 2010 | |
| dc.date.submitted | 2010-08-16 | |
| dc.identifier.citation | 1. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336(26):1855-9.
2. Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126-35. 3. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17(2):71-91. 4. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, Krogsgaard K, Degos F, Carneiro de Moura M, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21(1):77-82. 5. Yu MW, Shih WL, Lin CL, Liu CJ, Jian JW, Tsai KS, Chen CJ. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol 2008;26(34):5576-82. 6. Yu MW, Chang HC, Chen PJ, Liu CJ, Liaw YF, Lin SM, Lee SD, Lin SC, Lin CL, Chen CJ. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002;31(5):1008-15. 7. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92(14):1159-64. 8. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155(4):323-31. 9. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85(4):498-502. 10. Chen ZM, Liu BQ, Boreham J, Wu YP, Chen JS, Peto R. Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. Int J Cancer 2003;107(1):106-12. 11. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339(8799):943-6. 12. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, Wu MH, Wu WP, Wang LW, Wang Q, Huang GT, Yang PM, Lee HS, Santella RM. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996;67(5):620-5. 13. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997;27(2):320-30. 14. Marrero CR, Marrero JA. Viral hepatitis and hepatocellular carcinoma. Arch Med Res 2007;38(6):612-20. 15. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347(3):168-74. 16. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97(4):265-72. 17. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003;124(2):327-34. 18. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678-86. 19. Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol 2002;37(3):355-63. 20. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S113-9. 21. Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin. Cancer Res 1989;49(23):6493-7. 22. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996;77(9):1781-6. 23. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998;82(9):1643-8. 24. Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999;94(3):650-4. 25. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Palareti G, Gozzetti G. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995;1(4):249-55. 26. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37(5):1114-21. 27. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 2000;95(4):1036-40. 28. Yamagamim H, Moriyama M, Matsumura H, Aoki H, Shimizu T, Saito T, Kaneko M, Shioda A, Tanaka N, Arakawa Y. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 2002;95(4):824-34. 29. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50. 30. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984;4(2):136-46. 31. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350(16):1646-54. 32. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99(6):1160-74. 33. Thampanitchawong P, Piratvisuth T. Liver biopsy:complications and risk factors. World J Gastroenterol 1999;5(4):301-304. 34. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97(10):2614-8. 35. Mukherjee S, Sorrell MF. Noninvasive tests for liver fibrosis. Semin Liver Dis 2006;26(4):337-47. 36. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S57-64. 37. Halfon P, Bourliere M, Penaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, Portal I, Allemand I, Rosenthal-Allieri A, Ouzan D. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005;4:6. 38. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42(4):558-63. 39. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004;99(2):271-9. 40. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357(9262):1069-75. 41. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, Lin R, Samarasinghe D, Liddle C, McCaughan GW, George J. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004;39(5):1239-47. 42. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36(4 Pt 1):986-92. 43. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127(6):1704-13. 44. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:34. 45. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38(2):481-92. 46. Thabut D, Trabut JB, Massard J, Rudler M, Muntenau M, Messous D, Poynard T. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver Int 2006;26(3):271-8. 47. Nandi A, Estess P, Siegelman MH. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem 2000;275(20):14939-48. 48. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998;5(3):187-92. 49. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000;15(8):945-51. 50. Zeng G, Wang Z, Wen S, Jiang J, Wang L, Cheng J, Tan D, Xiao F, Ma S, Li W, Luo K, Naoumov NV, Hou J. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 2005;12(6):609-17. 51. Granerus M, Schofield P, Bierke P, Engstrom W. Growth factors and apoptosis in development. The role of insulin like growth factor I and TGFbeta1 in regulating cell growth and cell death in a human teratocarcinoma derived cell line. Int J Dev Biol 1995;39(5):759-64. 52. Grasl-Kraupp B, Rossmanith W, Ruttkay-Nedecky B, Mullauer L, Kammerer B, Bursch W, Schulte-Hermann R. Levels of transforming growth factor beta and transforming growth factor beta receptors in rat liver during growth, regression by apoptosis and neoplasia. Hepatology 1998;28(3):717-26. 53. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146. 54. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994;370(6488):341-7. 55. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341(10):738-46. 56. Yang L, Qiu CX, Ludlow A, Ferguson MW, Brunner G. Active transforming growth factor-beta in wound repair: determination using a new assay. Am J Pathol 1999;154(1):105-11. 57. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997;8(1):21-43. 58. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31(6):220-7. 59. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010;10(6):415-24. 60. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359(6397):693-9. 61. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21(1):57-69. 62. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331(19):1286-92. 63. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003;100(15):8621-3. 64. Akhurst RJ, Derynck R. TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol 2001;11(11):S44-51. 65. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29(2):117-29. 66. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999;17(2):607-14. 67. Friedman SL, Rockey DC, McGuire RF, Maher JJ, Boyles JK, Yamasaki G. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology 1992;15(2):234-43. 68. Naito M, Hasegawa G, Ebe Y, Yamamoto T. Differentiation and function of Kupffer cells. Med Electron Microsc 2004;37(1):16-28. 69. Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 1987;84(16):5788-92. 70. Reibman J, Meixler S, Lee TC, Gold LI, Cronstein BN, Haines KA, Kolasinski SL, Weissmann G. Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways. Proc Natl Acad Sci U S A 1991;88(15):6805-9. 71. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007;7(6):443-53. 72. Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1999;1(15):1297-304. 73. Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M. Transforming growth factor beta and cancer. Cancer Treat Rev 1995;21(4):367-403. 74. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52. 75. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441(7090):235-8. 76. Wahl SM. Transforming growth factor-beta: innately bipolar. Curr Opin Immunol 2007;19(1):55-62. 77. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1999;1(15):1349-65. 78. Wells RG. Fibrogenesis. V. TGF-beta signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000;279(5):G845-50. 79. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115(2):209-18. 80. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1995;1(4):282-4. 81. Nakamura M, Katano M, Kuwahara A, Fujimoto K, Miyazaki K, Morisaki T, Mori M. Transforming growth factor beta1 (TGF-beta1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br J Cancer 1998;78(10):1373-8. 82. Li X, Yue ZC, Zhang YY, Bai J, Meng XN, Geng JS, Fu SB. Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer. J Clin Lab Anal 2008;22(3):164-71. 83. Papadopoulou E, Anagnostopoulos K, Tripsianis G, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Neoplasma 2008;55(3):229-38. 84. Wu CF, Yu MW, Lin CL, Liu CJ, Shih WL, Tsai KS, Chen CJ. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29(1):106-12. 85. Sung FY, Jung CM, Wu CF, Lin CL, Liu CJ, Liaw YF, Tsai KS, Yu MW. Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology 2009;137(5):1687-97. 86. Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal 1999;5(2):99-112. 87. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-61. 88. Murakami S. Hepatitis B virus X protein: structure, function and biology. Intervirology 1999;42(2-3):81-99. 89. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 2001;36(10):651-60. 90. Yoo YD, Ueda H, Park K, Flanders KC, Lee YI, Jay G, Kim SJ. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Invest 1996;97(2):388-95. 91. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000;12(6):677-81. 92. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 1994;73(9):2275-9. 93. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93(14):1054-61. 94. Delpuech O, Trabut JB, Carnot F, Feuillard J, Brechot C, Kremsdorf D. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene 2002;21(18):2926-37. 95. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 1999;85(3):554-61. 96. Shirai Y, Kawata S, Ito N, Tamura S, Takaishi K, Kiso S, Tsushima H, Matsuzawa Y. Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992;83(7):676-9. 97. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997;76(2):244-50. 98. Lin Y, Nakachi K, Ito Y, Kikuchi S, Tamakoshi A, Yagyu K, Watanabe Y, Inaba Y, Kazuo T. Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults. Dis Markers 2009;27(1):23-8. 99. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev 2000;11(1-2):133-45. 100. Porreca E, Di Febbo C, Vitacolonna E, Baccante G, Di Castelnuovo A, Angelini A, Febo F, Di Nisio M, Cuccurullo F. Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens 2002;15(9):759-65. 101. Ghosh J, Murphy MO, Turner N, Khwaja N, Halka A, Kielty CM, Walker MG. The role of transforming growth factor beta1 in the vascular system. Cardiovasc Pathol 2005;14(1):28-36. 102. Grainger DJ. TGF-beta and atherosclerosis in man. Cardiovasc Res 2007;74(2):213-22. 103. Derhaschnig U, Shehata M, Herkner H, Bur A, Woisetschlager C, Laggner AN, Hirschl MM. Increased levels of transforming growth factor-beta1 in essential hypertension. Am J Hypertens 2002;15(3):207-11. 104. Esmatjes E, Flores L, Lario S, Claria J, Cases A, Inigo P, Campistol JM. Smoking increases serum levels of transforming growth factor-beta in diabetic patients. Diabetes Care 1999;22(11):1915-6. 105. Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Thorand B. Transforming growth factor-beta1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care 2009;32(10):1921-3. 106. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003;46(6):400-7. 107. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118(3):554-9. 108. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25(6):1097-107. 109. Wu BW, Wu Y, Wang JL, Lin JS, Yuan SY, Li A, Cui WR. Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells. World J Gastroenterol 2003;9(2):271-5. 110. Yutani S, Tanaka M, Mutsumoto H, Imai N, Sata M, Shichijo S, Harada M, Itoh K. Elevation of serum MAGE-4 protein levels and prediction of hepatocellular carcinogenesis in patients with liver cirrhosis. Jpn J Cancer Res 2002;93(4):453-8. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22192 | - |
| dc.description.abstract | 背景及目的：TGF-β1 為一多功能蛋白，參與免疫、發炎反應、肝纖維化、以及腫瘤生成。本研究目的為探討慢性B型肝炎病毒帶原者，其血漿TGF-β1濃度是否能預測肝細胞癌之危險性。
方法： 研究世代於1989至1992年間經由免費健檢收案進入研究，包括2903名B型肝炎表面抗原陽性之男性公務員接受血液檢體收集及訪視問卷。肝細胞癌病例的追蹤鑑定至2006年12月31日截止。透過病例世代研究設計，我們對164名肝細胞癌新發生病例及隨機抽樣獲得的1018名無癌症之個案分析血漿TGF-β1濃度。基線 TGF-β1的測量至肝細胞癌診斷期間由0.6年至16年（中位數：9.0年）。 結果：在調整其他危險因子下，血漿TGF-β1濃度的提高會顯著地增高罹患肝細胞癌之危險性。在肝細胞癌罹病風險預測模式(已包含：ALT、病毒相關因子、家族肝癌史、年齡、抽菸狀況、飲酒情形及身體質量指數)中加入 TGF-β1，亦會顯著地增加對肝細胞癌罹病風險的預測之準確度。 結論：我們的結果支持血漿TGF-β1有潛力作為肝細胞癌的一個生物標記。加入血漿TGF-β1於肝細胞癌危險性預測之演算模式，改善預測之準確性，然而，未來還需其他前瞻性研究的評估來證實。 | zh_TW |
| dc.description.abstract | Background & Aims: Transforming growth factor-β1 (TGF-β1) is a multifunction protein, which is involved in immunity, inflammation, fibrogenesis, and tumorigenesis. The aim of this study was to determine whether pre-diagnostic plasma levels of TGF-β1 could predict the risk of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) carriers.
Methods: Between 1989 and 1992, 2903 male hepatitis B surface antigen-positive government employees were recruited with blood collection and questionnaire interview during free physical examination. We identified HCC events occurring between study entry and December 31, 2006. Using a case-cohort study design, we analyzed the concentrations of TGF-β1 in plasma from 164 incident HCC cases and a random sample of 1018 examines free of cancer at baseline. Levels of TGF-β1 was measured in the baseline samples that were taken 0.6 to 16 years (median: 9.0 years) before the diagnosis of HCC. Results: Elevated plasma levels of TGF-β1 were significantly associated with an increased risk of HCC after adjustment for other HCC risk factors. The addition of TGF-β1 to known HCC risk factors (including alanine aminotransferase, various viral factors, family history of HCC, age, smoking, alcohol consumption and body mass index) improved the ability to predict future HCC events. Conclusions: Our findings support plasma TGF-β1 as a potential biomarker for HCC. The addition of plasma TGF-β1 to algorithms for prediction of HCC risk could improve accuracy; however, future prospective evaluation is warranted. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T04:13:37Z (GMT). No. of bitstreams: 1 ntu-99-R97842008-1.pdf: 401081 bytes, checksum: beffd6dbb1e510a7ee4deb766160cf4c (MD5) Previous issue date: 2010 | en |
| dc.description.tableofcontents | 中文摘要 i
英文摘要 ii 研究背景 1 材料與方法 7 研究世代 7 病例世代研究 7 實驗分析 8 資料整理與統計分析 9 結果 10 討論 13 參考文獻 17 附錄一 46 | |
| dc.language.iso | zh-TW | |
| dc.subject | B型肝炎病毒 | zh_TW |
| dc.subject | TGF-β1 | zh_TW |
| dc.subject | 肝細胞癌 | zh_TW |
| dc.subject | Hepatocellular Carcinoma | en |
| dc.subject | HBV | en |
| dc.subject | TGF-β1 | en |
| dc.title | 血漿TGF-β1濃度和B型肝炎相關之肝細胞癌危險性：前瞻型研究 | zh_TW |
| dc.title | Prospective Evaluation of Plasma Levels of Transforming Growth Factor-β1 and Risk of Hepatocellular Carcinoma in Hepatitis B | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 98-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 莊雅惠(Ya-Hui Chuang) | |
| dc.contributor.oralexamcommittee | 蔡孟勳(Mong-Hsun Tsai),熊昭(Chao Agnes Hsiung),吳肇卿(Jaw-Ching Wu) | |
| dc.subject.keyword | TGF-β1,肝細胞癌,B型肝炎病毒, | zh_TW |
| dc.subject.keyword | TGF-β1,Hepatocellular Carcinoma,HBV, | en |
| dc.relation.page | 46 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2010-08-16 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-99-1.pdf 未授權公開取用 | 391.68 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。